MA35443B1 - Composes benzofuranes pour le traitement d'infections par le virus de l'hepatite c - Google Patents

Composes benzofuranes pour le traitement d'infections par le virus de l'hepatite c

Info

Publication number
MA35443B1
MA35443B1 MA36832A MA36832A MA35443B1 MA 35443 B1 MA35443 B1 MA 35443B1 MA 36832 A MA36832 A MA 36832A MA 36832 A MA36832 A MA 36832A MA 35443 B1 MA35443 B1 MA 35443B1
Authority
MA
Morocco
Prior art keywords
infections
treatment
hepatitis
virus
compounds
Prior art date
Application number
MA36832A
Other languages
English (en)
Inventor
Pek Yoke Chong
John F Miller
Andrew James Peat
John Brad Shotwell
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47746761&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35443(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA35443B1 publication Critical patent/MA35443B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des composés de la formule (i) et des sels de ceux-ci, des compositions pharmaceutiques comportant lesdits composés, et des utilisations de tels composés dans le traitement ou la prévention d'infections virales, telles que des infections par le vhc, et des maladies associées à de telles infections.
MA36832A 2011-08-19 2014-03-13 Composes benzofuranes pour le traitement d'infections par le virus de l'hepatite c MA35443B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161525440P 2011-08-19 2011-08-19
US201261650681P 2012-05-23 2012-05-23
PCT/US2012/050268 WO2013028371A1 (fr) 2011-08-19 2012-08-10 Composés benzofuranes pour le traitement d'infections par le virus de l'hépatite c

Publications (1)

Publication Number Publication Date
MA35443B1 true MA35443B1 (fr) 2014-09-01

Family

ID=47746761

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36832A MA35443B1 (fr) 2011-08-19 2014-03-13 Composes benzofuranes pour le traitement d'infections par le virus de l'hepatite c

Country Status (38)

Country Link
US (2) US8927593B2 (fr)
EP (2) EP2744332B1 (fr)
JP (2) JP6367712B2 (fr)
KR (1) KR101913800B1 (fr)
CN (1) CN103732065B (fr)
AR (1) AR087563A1 (fr)
AU (1) AU2012299295B2 (fr)
BR (1) BR112014002845A2 (fr)
CA (1) CA2844086A1 (fr)
CL (2) CL2014000393A1 (fr)
CO (1) CO6862153A2 (fr)
CR (1) CR20140078A (fr)
CY (1) CY1118399T1 (fr)
DK (1) DK2744332T3 (fr)
DO (1) DOP2014000034A (fr)
EA (1) EA032841B1 (fr)
ES (1) ES2611731T3 (fr)
HR (1) HRP20161743T1 (fr)
HU (1) HUE030300T2 (fr)
IL (1) IL230487B (fr)
IN (1) IN2014CN00572A (fr)
JO (1) JO3281B1 (fr)
LT (1) LT2744332T (fr)
MA (1) MA35443B1 (fr)
ME (1) ME02588B (fr)
MX (1) MX354676B (fr)
PE (1) PE20141201A1 (fr)
PH (1) PH12014500385A1 (fr)
PL (1) PL2744332T3 (fr)
PT (1) PT2744332T (fr)
RS (1) RS55462B1 (fr)
SG (1) SG10201606883QA (fr)
SI (1) SI2744332T1 (fr)
SM (2) SMT201700028T1 (fr)
TW (1) TWI538915B (fr)
UY (1) UY34274A (fr)
WO (1) WO2013028371A1 (fr)
ZA (1) ZA201401020B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12014500381A1 (en) 2011-08-17 2021-07-12 Glaxosmithkline Llc Therapeutic methods
US8927593B2 (en) 2011-08-19 2015-01-06 Glaxo Group Limited Benzofuran compounds for the treatment of hepatitis C virus infections
MA40844A (fr) 2014-11-10 2017-09-20 Glaxosmithkline Ip No 2 Ltd Compositions pharmaceutiques à action prolongée pour l'hépatite c
US10308937B2 (en) * 2014-11-10 2019-06-04 Glaxosmithkline Intellectual Property (No. 2) Limited Combination long acting compositions and methods for Hepatitis C
KR20180006522A (ko) 2016-07-07 2018-01-18 삼성디스플레이 주식회사 액정 조성물 및 이를 포함하는 액정 표시 장치
US11738088B2 (en) 2016-08-01 2023-08-29 University of Pittsburgh—of the Commonwealth System of Higher Education Boryl ethers, carbonates, and cyclic acetals as oxidatively-triggered drug delivery vehicles
BR112019018230A2 (pt) * 2017-03-02 2020-07-21 Assembly Biosciences, Inc. compostos de sulfamida cíclica e métodos de sua utilização
JP7133023B2 (ja) * 2018-01-17 2022-09-07 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド Ｐｉ４ｋｉｉｉベータ阻害剤
US20230038124A1 (en) * 2019-10-25 2023-02-09 Sumitomo Pharma Co., Ltd. Novel substituted condensed ring compound
CN111026203B (zh) * 2019-12-02 2021-01-26 宁波德晶元科技有限公司 一种适用于真空热水壶的加热控制方法与系统
WO2022133420A1 (fr) * 2020-12-18 2022-06-23 Boehringer Ingelheim Animal Health USA Inc. Composés pyrazole contenant du bore, compositions comprenant ceux-ci, méthodes et utilisations associées

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
WO2001002424A2 (fr) * 1999-07-07 2001-01-11 Du Pont Pharmaceuticals Company Inhibiteurs de la protease du virus de l'hepatite c a base d'acide boronique peptide
CA2435146C (fr) 2001-01-25 2011-03-29 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Formulation de composes d'acide boronique
US7265152B2 (en) * 2002-11-01 2007-09-04 Viropharma Incorporated Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases
BRPI0619132A2 (pt) 2005-12-01 2011-09-13 Wyeth Corp composto métodos para inibir a replicação de um vìrus de hepatite c, para tratar ou prevenir uma infecção viral de hepatite c em um mamìfero e para inibir rna polimerase dependente do rna de hepatite c, e, composição farmacêutica
RU2642628C2 (ru) 2006-02-16 2018-01-25 Анакор Фармасьютикалз, Инк. Бор-содержащие малые молекулы в качестве противовоспалительных средств
BRPI0711155A2 (pt) * 2006-05-02 2011-08-23 Anacor Pharmaceuticals Inc terapêuticos contendo boro resistentes hidroliticamente e métodos de uso
US20070286822A1 (en) 2006-06-12 2007-12-13 Anacor Pharmaceuticals Inc. Compounds for the Treatment of Periodontal Disease
ES2569660T3 (es) * 2007-06-08 2016-05-12 Mannkind Corporation Inhibidores de la IRE-1alfa
GB0719366D0 (en) * 2007-10-03 2007-11-14 Smithkline Beecham Corp Compounds
WO2009111676A2 (fr) 2008-03-06 2009-09-11 Anacor Pharmaceuticals, Inc Petites molécules contenant du bore utilisées en tant qu'agents anti-inflammatoires
ATE539070T1 (de) * 2008-02-14 2012-01-15 Hoffmann La Roche Heterozyklische antivirale verbindungen
WO2009137493A1 (fr) 2008-05-05 2009-11-12 Wyeth Composés benzofurane substitués en position 2 pour traiter une infection par le virus de l'hépatite c
WO2009137500A1 (fr) * 2008-05-05 2009-11-12 Wyeth Composés de benzofurane substitués en 6 pour traiter l’infection par le virus de l’hépatite c
TW201008933A (en) 2008-08-29 2010-03-01 Hutchison Medipharma Entpr Ltd Pyrimidine compounds
WO2010027975A1 (fr) 2008-09-04 2010-03-11 Anacor Pharmaceuticals, Inc. Petites molécules contenant du bore
WO2011050284A1 (fr) * 2009-10-23 2011-04-28 Glaxosmithkline Llc Agents antiviraux de pyrazolylpyridine
AR080185A1 (es) * 2010-02-19 2012-03-21 Glaxo Group Ltd Derivados de acido boronico y benzofurano, composiciones farmaceuticas que los contienen,y uso de los mismos en el tratamiento y/o prevencion de infecciones virales, en particular por el virus de hepatitis c(hcv).
WO2011106929A1 (fr) 2010-03-02 2011-09-09 Merck Sharp & Dohme Corp. Inhibiteurs de polymérase du virus de l'hépatite c ns5b
TW201136919A (en) 2010-03-02 2011-11-01 Merck Sharp & Amp Dohme Corp Inhibitors of hepatitis C virus NS5B polymerase
AU2011329485A1 (en) * 2010-11-18 2013-04-18 Glaxo Group Limited Compounds
AU2011329486A1 (en) 2010-11-18 2013-04-18 Glaxo Group Limited Compounds
WO2013025975A1 (fr) * 2011-08-17 2013-02-21 Glaxosmithkline Llc Traitements combinés pour l'hépatite c
PH12014500381A1 (en) * 2011-08-17 2021-07-12 Glaxosmithkline Llc Therapeutic methods
US8927593B2 (en) 2011-08-19 2015-01-06 Glaxo Group Limited Benzofuran compounds for the treatment of hepatitis C virus infections

Also Published As

Publication number Publication date
CN103732065B (zh) 2016-10-26
UY34274A (es) 2013-04-05
TW201321390A (zh) 2013-06-01
CN103732065A (zh) 2014-04-16
BR112014002845A2 (pt) 2017-02-21
IN2014CN00572A (fr) 2015-04-03
US8927593B2 (en) 2015-01-06
MX2014001989A (es) 2014-02-27
LT2744332T (lt) 2017-01-10
CO6862153A2 (es) 2014-02-10
TWI538915B (zh) 2016-06-21
AU2012299295B2 (en) 2016-03-31
ES2611731T3 (es) 2017-05-10
MX354676B (es) 2018-03-15
PE20141201A1 (es) 2014-10-03
US20130237501A1 (en) 2013-09-12
JP2014527529A (ja) 2014-10-16
SG10201606883QA (en) 2016-10-28
SMT201700028T1 (it) 2017-03-08
WO2013028371A1 (fr) 2013-02-28
HUE030300T2 (en) 2017-04-28
IL230487A0 (en) 2014-03-31
EA032841B1 (ru) 2019-07-31
CA2844086A1 (fr) 2013-02-28
EP3199531A1 (fr) 2017-08-02
US9682999B2 (en) 2017-06-20
JP6367712B2 (ja) 2018-08-01
RS55462B1 (sr) 2017-04-28
EP2744332B1 (fr) 2016-10-26
ME02588B (fr) 2017-06-20
CY1118399T1 (el) 2017-06-28
AR087563A1 (es) 2014-04-03
US20150080343A1 (en) 2015-03-19
AU2012299295A1 (en) 2014-02-20
SI2744332T1 (sl) 2017-01-31
IL230487B (en) 2019-06-30
EP2744332A1 (fr) 2014-06-25
CL2014000393A1 (es) 2014-08-01
CL2017000293A1 (es) 2017-10-06
EP2744332A4 (fr) 2015-01-14
PL2744332T3 (pl) 2017-03-31
PT2744332T (pt) 2017-01-24
DOP2014000034A (es) 2014-06-01
JP2017125010A (ja) 2017-07-20
KR101913800B1 (ko) 2018-11-01
ZA201401020B (en) 2020-11-25
EA201490213A1 (ru) 2014-07-30
CR20140078A (es) 2014-03-20
HRP20161743T1 (hr) 2017-02-24
SMT201700028B (it) 2017-03-08
KR20140054287A (ko) 2014-05-08
PH12014500385A1 (en) 2020-06-22
JO3281B1 (ar) 2018-09-16
DK2744332T3 (en) 2017-01-16

Similar Documents

Publication Publication Date Title
MA35132B1 (fr) 4-aryl-n-phényl-1,3,5-triazine-2- amines contenant un groupe sulfoximine
MA46490A1 (fr) Dérivés de nucléosides 4'- fluoro-2' - méthyle substitués
MA34765B1 (fr) Antagonistes des récepteurs de l'acide lysophosphatidique et utilisations de ceux-ci
MA35750B1 (fr) Dérivés de nucléoside substitué 2',4'-difluoro-2'-méthyle en tant qu'inhibiteurs de la réplication de l'arn du vhc (virus de l'hépatite c)
MA34896B1 (fr) Inhibiteurs du virus de l'hepatite c
MA29240B1 (fr) Derives d'indole pour le traitement d'infections virales
MA39777B1 (fr) Composes organiques de la famille des monobactams pour le traitement d'infections bactériennes
MA41338A (fr) Composés de pyrazine pour le traitement de maladies infectieuses
MA37712B1 (fr) Inhibiteurs macrocycliques de virus flaviviridae
MY186986A (en) Compositions and methods of use of phorbol esters
MA37942A2 (fr) Hétéroaryldihydropyrimidines d'acide 6-aminé pour le traitement et la prophylaxie d'une infection par le virus de l'hépatite b
MA35104B1 (fr) Inhibiteur du virus de l'hepatite c
MA34392B1 (fr) Pyrimidines en tant qu'agents antiviraux
MA33731B1 (fr) Inhibiteurs du virus de l'hépatite c
MX2013005478A (es) Compuestos heterociclicos condensados antivirales.
MA33642B1 (fr) Composés chimiques
MA38182A1 (fr) Compositions pharmaceutiques a action prolongée pur une utilisation dans le traitement ou la prévention d'infections par le virus de l’immunodéficience humaine (vih)
MA39721A (fr) Nouvelles héteroaryldihydropyrimidines condensées en position 6 pour le traitement et la prophylaxie d'une infection à virus de l'hépatite b
MA45598B1 (fr) Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
MA37891A1 (fr) Alcoxypyrazoles comme activateurs de guanylate cyclase soluble
MA35342B1 (fr) Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase
MA39165A1 (fr) Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires
CA2878796C (fr) Derives de pyridinone comme inhibiteurs de la transglutaminase tissulaire
JO3281B1 (ar) مركبات بينزوفوران لمعالجة عدوى فيروس إلتهاب الكبد الوبائي
MA33760B1 (fr) Dérivés spirolactames et leurs utilisations